Moderna said the submission is based on the FDA's recommendation that vaccine makers update their jabs to target omicron subvariant XBB.1.5.
already began to develop versions of their vaccines targeting XBB.1.5 months before the FDA's recommendation.
"The agility of our mRNA platform has enabled us to update Spikevax, Moderna's COVID-19 vaccine, to target XBB variants with speed and clinical rigor," Moderna CEO Stéphane Bancel said in a statement. Preclinical trial data on mice suggests a monovalent vaccine targeting XBB.1.5 produces a more robust immune response against the currently circulating XBB variants than the company's authorized bivalent shot targeting the BA.4 and BA.5 strains, according to a Moderna presentation last week.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer, Moderna and Novavax gear up for fall Covid vaccine rollout with an important head startThe FDA's strain selection puts Pfizer, Moderna and Novavax on track to deliver updated coronavirus shots in time for the fall.
Read more »
FDA Warns of Tattoo Ink Tied to Dangerous InfectionsThe FDA released the new draft guidance aiming to reduce the use of pathogen-contaminated tattoo ink, which can cause stubborn infections that are especially hard to treat, dermatologists said.
Read more »
US FDA approves Eli Lilly-Boehringer's diabetes drugs for childrenThe U.S. Food and Drug Administration (FDA) on Tuesday approved Eli Lilly and partner Boehringer Ingelheim's drugs Jardiance and Synjardy to treat type 2 diabetes in children.
Read more »
FDA to test out nutrition labels on the front of food packaging | CNNGetting nutritional information is not always as simple and convenient as it should be, experts say. The FDA is testing out new labels on the front of packages to try to combat that.
Read more »
FDA OKs Empagliflozin for Children With Type 2 DiabetesThe FDA has approved empagliflozin and empagliflozin combined with metformin for the treatment of type 2 diabetes in children aged 10 years and older.
Read more »
FDA Approves Talazoparib for Metastatic Prostate CancerThe oral PARP inhibitor talazoparib in combination with enzalutamide provides a new treatment option for patients with HRR gene–mutated metastatic castration-resistant prostate cancer.
Read more »